Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-11: Belantamab Mafodotin in Japanese Patients with Relapsed/Refractory Multiple Myeloma
NCT03828292Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2019
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Dose Limiting Toxicities, Number of Participants With Adverse Events and Serious Adverse Events and 4 more. Started Mar 2019; status: completed.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03828292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828292.